News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lithera Announces Notice of Allowance for a Key Patent Application for LIPO-102, a Novel Treatment for Localized Fat Reduction


10/12/2010 10:35:38 AM

SAN DIEGO, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. Once issued, this patent will afford the company market exclusivity for LIPO-102 into 2028. This news follows Lithera's recent announcement of positive results from a Phase II clinical trial of LIPO-102 showing dose- and time-related reductions in mean abdominal circumference and volume.

Read at GlobeNewswire

comments powered by Disqus
Lithera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES